Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); For A Few Pennies More, WPI Takes Big Time Price Increases
Tweet Send to a FriendGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
14 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Rating Summary:
14 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 24
Trade WPI Now!
Needham & Company maintains a 'Hold' on Watson Pharmaceuticals (NYSE: WPI).
Analyst, Elliot Wilbur, said, "Generic leaders are supposed to consolidate market share and, if possible, raise price when afforded the rare opportunity to do so, and that is exactly what WPI has done on its market-leading hydrocodone/APAP line of products. Though this product line has diminished in relative importance to WPI over the years with annualized sales just north of $200.0MM, the price increases add some decent incremental EPS power given WPI’s declining tax rate and low share base."
"Upside risk to our stance on WPI would be a greater than expected decline in tax rate paid by WPI, while risk to the downside could result from moving hydrocodone products to Schedule II classification."
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $72.20 yesterday, with a 52 week range of $55.00-$77.73.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Elliot Wilbur, said, "Generic leaders are supposed to consolidate market share and, if possible, raise price when afforded the rare opportunity to do so, and that is exactly what WPI has done on its market-leading hydrocodone/APAP line of products. Though this product line has diminished in relative importance to WPI over the years with annualized sales just north of $200.0MM, the price increases add some decent incremental EPS power given WPI’s declining tax rate and low share base."
"Upside risk to our stance on WPI would be a greater than expected decline in tax rate paid by WPI, while risk to the downside could result from moving hydrocodone products to Schedule II classification."
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $72.20 yesterday, with a 52 week range of $55.00-$77.73.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: UBS Downgrades Carnival (CCL) to Neutral; Worst May Not Be Behind
- First Time Cruisers Pass on Carnival (CCL); Wells Fargo Cuts to Market Perform
- UPDATE: Sterne Agee Downgrades Beazer Homes (BZH) to Neutral
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & Company, Raising Prices
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
